Advanced non small lung cancer
Conditions
Brief summary
Objective response rate according to RECIST 1.1., ORR; defined as complete or partial response at any timepoint during study period.
Detailed description
Secondary Endpoint: Progression-free survival (PFS), Overall survival (OS). Exploratory Endpoint: Safety & tolerability of fexofenadine in terms of haematologic and nonhaematologic side effects as assessed by the investigators. Quality of life (QoL) with focus on sleeping behavior in patients receiving fexofenadine assessed by the Pittsburgh Sleep Quality Index (PSQI), EORTC QLQ-c30 questionnaire and Lung Cancer Symptom Scale (LCSS). Analysis of predictive factors for the enhancement of immunoth
Interventions
DRUGAllegra 120 mg Filmtabletten
Sponsors
Medical University Of Vienna
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Objective response rate according to RECIST 1.1., ORR; defined as complete or partial response at any timepoint during study period. | — |
Secondary
| Measure | Time frame |
|---|---|
| Secondary Endpoint: Progression-free survival (PFS), Overall survival (OS). Exploratory Endpoint: Safety & tolerability of fexofenadine in terms of haematologic and nonhaematologic side effects as assessed by the investigators. Quality of life (QoL) with focus on sleeping behavior in patients receiving fexofenadine assessed by the Pittsburgh Sleep Quality Index (PSQI), EORTC QLQ-c30 questionnaire and Lung Cancer Symptom Scale (LCSS). Analysis of predictive factors for the enhancement of immunoth | — |
Countries
Austria
Outcome results
None listed